Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                About MCMi

About MCMi

                        MCMi News and Events
          MCMi Newsletters
          Publications and Reports
          Medical Countermeasure Resources
          What are Medical Countermeasures?
          MCMi History Home
          Emergency Preparedness and Response
          Counterterrorism and Emerging Threats
          Medical Countermeasures Initiative (MCMi)
          About MCMi
          Publications and ReportsAbout MCMi Publications and Reports
  
  	
    Subscribe to Email Updates
    Share
    Post
    Linkedin

    Email
    PrintFDA Medical Countermeasures Initiative (MCMi) reports and annual program updates

FY 2022 MCMi Program Update

	MCMi Fiscal Year 2022 Program Update - about this report - download a printable PDF (PDF, 1.5 MB)
	MCMi Fiscal Year 2021 Program Update (PDF, 1.4 MB)
	MCMi Fiscal Year 2020 Program Update (PDF, 4.3 MB)
	MCM-related legal and policy presentations, publications and Q&As
	MCM regulatory science presentationsArchived MCMi reports (FY 2019 and earlier)
	MCMi Fiscal Year 2019 Program Update (PDF, 1.3 MB - ARCHIVED)
	MCMi Fiscal Year 2018 Program Update (PDF, 4 MB - ARCHIVED)
	MCMi Fiscal Year 2017 Program Update (PDF, 2.6 MB - ARCHIVED)
	MCMi Fiscal Year 2016 Program Update (PDF, 1.6 MB - ARCHIVED)
	MCMi Fiscal Year 2015 Program Update (PDF, 2.7 MB - ARCHIVED)
	MCMi Fiscal Year 2014 Program Update (PDF,1.3 MB - ARCHIVED)
	MCMi Fiscal Year 2013 Program Update (PDF, 1.3 MB - ARCHIVED)
	MCMi Year 2 Program Update (PDF, 291 KB - ARCHIVED), 2012
	MCMi Year 1 Status Report (PDF, 191 KB - ARCHIVED), 2011

Other FDA publications

FDA's Work to Combat the COVID-19 Pandemic (PDF, 4.9 MB) - Outlines much of the broad range of work the FDA is undertaking to combat the COVID-19 pandemic and prepare for future emergencies. (August 2022)
	FDA Office of the Chief Scientist reports:
	Focus Areas of Regulatory Science - Updated in 2022, this report outlines topics FDA has identified as needing continued targeted investment in regulatory science research to facilitate development of innovative products, provide data and methods to inform regulatory decision-making, and improve guidance to sponsors. Public health preparedness and response is a focus area, including medical countermeasures and preparedness for emerging infectious diseases. Please contact FARS@fda.hhs.gov with questions about this initiative.
		Advancing Alternative Methods at FDA - Read about the activities FDA scientists are undertaking to spur the development of new regulatory approaches that can help improve predictivity--and potentially replace, reduce and/or refine animal testing. (January 2021)
		FDA's Predictive Toxicology Roadmap - Published in December 2017 by the FDA's Toxicology Working Group, this roadmap describes FDA’s thoughts on viable ways to foster the development and evaluation of emerging toxicological methods and new technologies and incorporate them into FDA regulatory review.
	See our Antimicrobial Resistance Information from FDA page for FDA publications related to AMR
	See our Advanced Manufacturing page for FDA publications related to advanced manufacturingDepartment of Health and Human Services (HHS) Public Health Emergency Medical Countermeasures Enterprise (PHEMCE), Assistant Secretary for Preparedness and Response (ASPR), and other federal reports

In October 2022, HHS announced actions the department will take following National Security Memorandum 15, signed by President Biden, directing implementation of the 2022 National Biodefense Strategy and Implementation Plan for Countering Biological Threats, Enhancing Pandemic Preparedness, and Achieving Global Health Security (PDF, 547 KB). The strategy and implementation plan detail a coordinated approach to address the challenges from naturally occurring, deliberate, and accidental biological threats. These threats are among the most serious threats facing the U.S. and the international community. The 2022 strategy builds on the 2018 National Biodefense Strategy, incorporating lessons learned during the COVID-19 pandemic, and laying out a comprehensive implementation plan with bold, concrete actions to transform our health security.
	Essential Medicines Report Now Available - The nation’s first Essential Medicines Supply Chain and Manufacturing Resilience Assessment by the U.S. government was released by HHS/ASPR. The assessment addresses pharmaceutical supply chain constraints identified in the Biden-Harris Administration’s 100-day supply chain review report, specifically those constraints affecting critical medicines on FDA’s essential medicines list. Download the full report here. (May 2022)
	Executive Order 14017 on America’s Supply Chains - Keeping the U.S. drug supply chain secure, robust, and resilient is essential for the health and national security, and economic prosperity of the United States during emergencies like the COVID-19 pandemic. As part of our vital mission to protect and promote public health, FDA plays a critical role in this effort, including by overseeing the regulation of a majority of the Nation’s medical and food products. On February 24, 2021, President Biden signed Executive Order 14017 to secure America’s critical supply chains. The Executive Order directed the Administration to: (1) launch an immediate 100-day review and strategy development process to identify and address vulnerabilities in the supply chains of four key product sectors, including pharmaceuticals and active pharmaceutical ingredients (API); and (2) submit sectoral supply chain assessment reports within one year of the date of the order, including a report on supply chains for the public health and biological preparedness industrial base and a report on supply chains for the production of agricultural commodities and food products.
	National Health Security Strategy (NHSS), published by HHS ASPR
	U.S. Health Security National Action Plan: Strengthening Implementation of the International Health Regulations (PDF, 2.1 MB), published by HHS/ASPR, and based on the 2016 Joint External Evaluation, October 2018 *- more about this plan*
	Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Strategy and Implementation Plan, published by HHS ASPR
	HHS Framework for Guiding Funding Decisions about Proposed Research Involving Enhanced Potential Pandemic Pathogens (HHS P3CO Framework - PDF, 718 KB), December 2017 - *also see NIH Lifts Funding Pause on Gain-of-Function Research*Related Links

MCM-Related Counterterrorism Legislation

                                                                                  Content current as of:
      06/07/2023
              
              
Topic(s)
			  Research
				    				       				    				       Public Awareness
				       				    				       Emergency Response
				       				    				       Drug Shortage
				       				    				       Terrorism
				       				    				       RadiologicalLaw(s) & Regulation(s)
			  Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 (PAHPRA)About MCMi

          
                        MCMi News and Events
          MCMi Newsletters
          Publications and Reports
          Medical Countermeasure Resources
          What are Medical Countermeasures?
          MCMi History
 Receive alerts when we post new MCMi reports
                        Sign up to receive email alerts on emergency preparedness and response topics from FDA, including medical countermeasures and emerging infectious diseases.
    Enter your email address to subscribe:
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop